SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, to develop an autoinjector for clinical and potential commercial supply of MoonLake鈥檚 Nanobody庐 sonelokimab based on SHL Medical鈥檚 Molly庐 autoinjector technology.
Sonelokimab is MoonLake Immunotherapeutics鈥� investigational anti-IL-17 A/F Nanobody technology designed to more directly target sites of inflammation and penetrate difficult-to-reach inflamed tissues and joints. A ~40 kDa molecule, sonelokimab can be delivered subcutaneously by patients via self-injection devices, including in a patient-centric autoinjector format. Sonelokimab is currently in clinical development for several indications, including moderate-to-severe plaque-type psoriasis and hidradenitis suppurativa, a severely debilitating chronic skin condition resulting in irreversible tissue destruction.
The Molly autoinjector is a market-proven modular platform technology developed to help pharmaceutical and biotechnology companies reduce initial investments and expedite development timelines. The maturity of the Molly platform has made it a trusted drug delivery device solution, particularly for innovative biotechnology companies seeking to lower the risks for their autoinjector projects.
Refined over the years through SHL Medical鈥檚 team of experts and industry-leading efforts, the Molly technology is also indicative of how modularity built upon an established platform can enable efficient, scalable production geared towards the end goal of enabling patients鈥� independence. To date, a total of 17 combination products that leverage the Molly autoinjector technology have been approved in at least 69 countries, enabling home treatment in a wide range of therapeutic areas that require injectable medicines, including for dermatologic and inflammatory indications.
Under the scope of the agreement, SHL Medical will provide its device development expertise, assembly guidance, and production competencies to support the sonelokimab drug-device project. The collaboration highlights SHL Medical鈥檚 capabilities as a fully integrated, end-to-end solutions provider offering added value for its pharmaceutical and biotechnology partner鈥檚 autoinjector projects, from robust device solutions to production and after-market needs.
鈥淪HL Medical and MoonLake are united by our shared passion for pursuing innovation and going beyond to deliver novel therapies that help unlock value and improve patients鈥� lives,鈥� said SHL Medical CEO Ulrich Faessler. 鈥淲orking with MoonLake while sonelokimab is in development allows us to carry out strategies that best complement MoonLake鈥檚 clinical and commercial needs. We are excited about the collaboration and look forward to potentially bringing the innovative Nanobody technology for dermatologic and rheumatic inflammatory indications to patients worldwide.鈥�
Oliver Daltrop, chief technical officer of MoonLake Immunotherapeutics, added: 鈥淢oonLake is proud to be partnering with a world leader in advanced autoinjector development to provide sonelokimab for clinical and potentially commercial supply. As we actively plan for a Phase III programme and commercial readiness, SHL鈥檚 expertise will greatly enhance our ability to introduce sonelokimab in an autoinjector format that could provide a benefit for patients, if approved.鈥�
Note: Nanobody庐 and Nanobodies庐 are (registered) trademarks of Ablynx, a Sanofi company.